RS-2024-00461975

Development of CSF3 targeted Pre-clinical Candidate Human Monoclonal Antibody FB-101 for Pulmonary Fibrosis

FNCT Biotech, Inc.
FNCT BIOTECH
Fibrosis & Cancer Targeting Biotechnology

RESPIRATORY | **Candidate**

Product Type	Fully Human monoclonal Antibody (mAb), FB-101
Indication	Idiopathic Pulmonary Fibrosis (IPF)
Target	Pulmonary Fibrosis Patients
MoA(Mechanism of Action)	**Therapeutic effect for pulmonary fibrosis** • Suppression of TGF-β expression and inhibition of Smad2/3 phosphorylation • Inhibitory effect of myofibroblast properties maintenance • Inhibition of collagen accumulation and ECM factor expression
Competitiveness	• The mechanism of action of Pirfenidone and Nintedanib currently in clinical use, and drugs entering phase2/3 clinical trials is inhibition of ECM deposition including collagen degradation. Therefore, these drugs are merely symptomatic relief agents, not ultimate treatments • **FB-101** has clear pulmonary fibrosis therapeutic treatment effects such as regulation of TGF-β expression, regeneration of myofibroblasts, promotion of collagen degradation, rather than simple symptom relief
Development Stage	Candidate
Route of Administration	Intravenous (IV)

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund